⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Supplementary Figure 3 from ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

Gillian Vandekerkhove Andrew J. Murtha David C. Müller Maria Stephenson Kimia Rostin Aslı D. Munzur Carlos Vasquez-Rios Jussi Nikkola Joonatan Sipola Matti Annala Cameron Herberts Emily Fung Jaskirat Atwal Sadeem Al-Subaie Karan Parekh Cecily Q. Bernales Gráinne Donnellan Daygen L. Finch Krista Noonan Jenny J. Ko Güliz Özgün Lucia Nappi Christian Kollmannsberger Jean‐Michel Lavoie Sunil Parimi Tilman Todenhöfer Piet Ost Gang Wang Peter C. Black Corinne Maurice‐Dror Kim N.Bernhard J. Eigl Alexander W. Wyatt

View Full Paper

Ask AI

Bookmark

Share

Key Points

Breakage-fusion-bridge events indicate genomic instability in metastatic urothelial cancer.
Whole-genome sequencing of circulating tumor DNA revealed the presence of these events.
Analysis shows the connection between ctDNA and HER2 alterations in patients with advanced cancer.
Findings emphasize the importance of ctDNA as a potential biomarker for cancer progression.

Implication

Observational analysis highlights breakage-fusion-bridge events in circulating tumor DNA, suggesting insights into ERBB2/HER2 alterations.

Abstract

Supplementary Figure 3. Breakage-fusion-bridge (BFB) events inferred from whole-genome sequencing of circulating tumor DNA.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vandekerkhove et al. (2025) studied this question.

synapsesocial.com/papers/68bb5f076d6d5674bcd02b19 https://doi.org/10.1158/1078-0432.30029654

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 4 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
2Supplementary Figure 8 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
3Supplementary Figure 1 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
4Supplementary Figure 5 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
5Supplementary Figure 2 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025

More related papers

Supplementary Figure 7 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
Supplementary Figure 9 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025
Supplementary Figure 6 from <i>ERBB2</i>/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer2025